

Paclitaxel assisted balloon angioplasty of venous stenosis in haemodialysis access: PAVE trial

Submission date 28/10/2015	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 28/10/2015	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 08/11/2023	Condition category Circulatory System	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Chronic kidney disease (CKD) is a long-term condition where the kidneys do not work properly. In a healthy person, the kidneys are vital for filtering out the waste products and excess water in the blood, and converting them into urine. In patients suffering from CKD, the kidneys are unable to do this, and so the body is unable to get rid of the waste products building up in the blood. Haemodialysis is one of the most common treatments for CKD patients, and involves diverting the blood into an external machine so that it can be "cleaned", before being returned to the body. Haemodialysis requires direct access to the circulatory system (blood stream) and the best option for this is by creating an arteriovenous fistula (AVF), which is made by surgically joining an artery and a vein in the arm. AVFs have a limited lifespan, and over time become narrowed (stenosed) or blocked (thrombosed). This can lead to a patient being admitted to hospital to have emergency lines fitted in their neck, which can cause infection. The fistula can be used for haemodialysis again if it is "re-opened". This is done by inflating a small balloon inside the fistula to flatten any blockages against the artery wall (fistuloplasty). In many cases however, the narrowing (stenosis) can return, re-blocking the fistula. Studies have shown that in the legs and heart, using a balloon coated with certain drugs, such as paclitaxel, can prevent cells from multiplying and re-blocking the artery. The aim of this study is to find out whether using paclitaxel coating balloons in a fistuloplasty procedure can help to prevent later AVF stenosis.

Who can participate?

Adults who have a narrowed AVF, which has been used for haemodialysis at least 12 times.

What does the study involve?

Participants are randomly allocated to one of two groups. Both groups receive the standard fistuloplasty procedure, in which a plain balloon is inflated until the fistula becomes wide enough to become usable. Those in the first group then receive a second fistuloplasty with a balloon coated in a drug called paclitaxel, which is inserted and inflated until it touches the wall of the blood vessel and transfers the paclitaxel onto the blood vessel wall. Those in the second group receive a second fistuloplasty with a balloon which is not drug coated. Participants attend regular follow-up appointments so that the openness (patency) of the fistula can be monitored.

What are the possible benefits and risks of participating?

Participants who receive the drug coated balloon treatment may have the chance of a better outcome for their fistula. Risks of participating are minimal, however the fistuloplasty procedure may be uncomfortable and cause pain.

Where is the study run from?

Guy's Hospital, London (lead centre) and five other NHS hospitals in England (UK)

When is the study starting and how long is it expected to run for?

November 2015 to November 2017

Who is funding the study?

National Institute for Health Research (UK)

Who is the main contact?

Leanne Gardner, leanne.gardner@kcl.ac.uk

Contact information

Type(s)

Public

Contact name

Ms Leanne Gardner

Contact details

School of Immunology & Microbial Sciences

King's College London

5th Floor, Tower Wing

Guy's Hospital

Great Maze Pond

London

United Kingdom

SE1 9RT

+44 20 7188 1909

leanne.gardner@kcl.ac.uk

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

CPMS 20038

Study information

Scientific Title

Paclitaxel assisted balloon Angioplasty of Venous stenosis in haEmodialysis access: The PAVE trial. A multicentre double-blind randomised controlled trial in haemodialysis patients with a stenosis in a native arteriovenous fistula

Acronym

PAVE

Study objectives

The aim of this study is to compare the efficacy of additional paclitaxel-coated balloon fistuloplasty to plain balloon fistuloplasty only to preserve the patency of arteriovenous fistulae used for haemodialysis.

Ethics approval required

Old ethics approval format

Ethics approval(s)

London - Chelsea Research Ethics Committee, 12/05/2015, ref: 15/LO/0638

Study design

Double-blind multicentre randomized controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Other

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

Health condition(s) or problem(s) studied

Topic: Renal disorders; Subtopic: Renal disorders; Disease: All Renal disorders

Interventions

Participants are randomised into one of two arms.

Intervention arm: Participants will receive standard-of-care fistuloplasty with a plain balloon, followed directly by insertion of a paclitaxel-coated balloon.

Control arm: An identical procedure is followed, but using a placebo balloon that is not drug coated.

Follow-up for both trial arms is every 3 months post-treatment. Participants in both trial arms who have not reached the primary outcome measure at 6 months post-recruitment will be invited to undergo a protocol fistulogram. Follow-up length is variable, and between 1 and 3 years; follow-up will end when the last recruited participant has been followed for 1 year.

Intervention Type

Procedure/Surgery

Primary outcome measure

Time to end of target lesion primary patency* is determined through AVF imaging when patient is referred for a re-intervention, at any point during follow-up (1-3 years).

*Primary patency fails when any of the following occur:

1. Clinically driven re-intervention to the treatment segment
2. Thrombotic occlusion that includes the treatment segment
3. Surgical intervention that excludes the treatment segment from the access circuit
4. Abandonment of the AVF due to an inability to retreat the treatment segment

Secondary outcome measures

1. Angiographically determined late lumen loss; measured on a protocol fistulogram at 6 months by an independent core laboratory
2. The rate of angiographic binary re-stenosis; measured on a protocol fistulogram at 6 months by an independent core laboratory
3. Time to end of access circuit primary patency* measured at a referred re-intervention, at any point during follow-up (1-3 years)
4. Time to end of access circuit cumulative patency (when the AVF is abandoned, regardless of radiological or surgical intervention, with or without a thrombosis event) measured at a referred re-intervention, at any point during follow-up (1-3 years)
5. Procedural success determined by measuring residual stenosis ($\leq 30\%$) on post-procedure fistulogram, after treatment fistuloplasty
6. Number of thrombosis events measured at end of follow-up (1-3 years)
7. Total number of interventions measured at end of follow-up (1-3 years)
8. Adverse events (e.g. fistula rupture, infection) measured at end of follow-up (1-3 years)
9. Patient quality of life measured using the EuroQuol EQ-5D generic health survey, and the disease specific Patient (or Palliative care) Outcome Scale symptom score-renal (POS-S Renal) at baseline, 6, and 12 months

*Ends when any of the following occur:

1. Access circuit thrombosis
2. An intervention (either radiological or surgical) anywhere in the access circuit
3. The access circuit is abandoned due to an inability to treat any lesion

Overall study start date

01/05/2015

Completion date

04/10/2019

Eligibility

Key inclusion criteria

1. Patients (18 years or over) who have a native AVF in the arm that has been used for at least 12 consecutive dialysis sessions
2. An indication for a fistuloplasty as determined by the local clinical team
3. The access circuit is free of synthetic graft material or stents
4. A reduction of vessel diameter of greater than or equal to 50%, and a reference diameter of the outflow vein of at least 4 mm and less than the diameter of the largest available paclitaxel-coated balloon
5. A residual stenosis of 30% after plain balloon fistuloplasty

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

Planned Sample Size: 211; UK Sample Size: 211

Total final enrolment

212

Key exclusion criteria

1. Patient unable to give informed consent
2. Patient unwilling or unable to comply with all study-related procedures
3. Systemic or local (to the fistula) infection treated for less than 10 days prior to the study procedure
4. Synchronous venous lesion, with a reduction of vessel diameter of greater than or equal to 50% measured angiographically, in the same access circuit
5. Location of stenosis beyond the thoracic inlet
6. Thrombosed (failed) dialysis circuit at time of treatment
7. Women who are breastfeeding, pregnant or are intending to become pregnant or men intending to father children, within 2 years of study treatment
8. Known hypersensitivity or contraindication to contrast medium which cannot be adequately pre-medicated
9. Known hypersensitivity or contraindication to paclitaxel

Date of first enrolment

29/10/2015

Date of final enrolment

31/10/2017

Locations

Countries of recruitment

England

United Kingdom

Study participating centre**Guy's Hospital**

Guy's and St Thomas' NHS Foundation Trust

Great Maze Pond

London

United Kingdom

SE1 9RT

Study participating centre**King's College Hospital**

King's College Hospital NHS Foundation Trust

Denmark Hill

London

United Kingdom

SE5 9RS

Study participating centre**Royal Free Hospital**

Royal Free London NHS Foundation Trust

Pond Street

London

United Kingdom

NW3 2QG

Study participating centre**Lister Hospital**

East and North Hertfordshire NHS Trust

Coreys Mill Lane

Stevenage

United Kingdom

SG1 4AB

Study participating centre**Kent and Canterbury Hospital**

East Kent Hospitals University NHS Foundation Trust

Ethelbert Road

Canterbury
United Kingdom
CT1 3NG

Study participating centre
Royal Sussex County Hospital
Brighton and Sussex University Hospitals NHS Trust
Eastern Road
Brighton
United Kingdom
BN2 5BE

Sponsor information

Organisation
Kings College London

Sponsor details
MRC Centre for Transplantation
Guy's Hospital
Great Maze Pond
London
England
United Kingdom
SE1 9RT

Sponsor type
Hospital/treatment centre

Website
<http://www.kcl.ac.uk>

ROR
<https://ror.org/0220mzb33>

Funder(s)

Funder type
Government

Funder Name
National Institute for Health Research

Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

The results of this project will be communicated to the research community through clinical and scientific national and international meetings. The findings are likely to be presented as oral presentations and published as abstracts on the relevant organisation's website. The formal result of the clinical trial will be published in a scientific journal.

Intention to publish date

01/04/2020

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article	protocol	12/05/2016		Yes	No
Results article		01/08/2021	03/08/2021	Yes	No
HRA research summary			28/06/2023	No	No
Results article		01/09/2021	08/11/2023	Yes	No